Arca Biopharma Stock Today

ABIO
 Stock
  

USD 2.06  0.08  3.74%   

Market Performance
0 of 100
Odds Of Distress
Less than 6
Arca Biopharma is selling for 2.06 as of the 1st of October 2022. This is a -3.74 percent decrease since the beginning of the trading day. The stock's open price was 2.14. Arca Biopharma has only a 6 % chance of going through financial distress over the next few years, but has generated negative returns over the last 90 days. Equity ratings for Arca Biopharma are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 7th of August 2021 and ending today, the 1st of October 2022. Click here to learn more.
ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. The company was incorporated in 2004 and is headquartered in Westminster, Colorado. Arca Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 14.41 M outstanding shares of which 71.36 K shares are presently shorted by private and institutional investors with about 1.51 trading days to cover. More on Arca Biopharma

Moving together with Arca Biopharma

+0.74HPQHp Inc Fiscal Year End 22nd of November 2022 PairCorr
Follow Valuation Odds of Bankruptcy
Check how we calculate scores

Arca Biopharma Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Arca Biopharma's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Arca Biopharma or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Arca Biopharma generated a negative expected return over the last 90 days
The company reported the previous year's revenue of 25.55 M. Net Loss for the year was (18.49 M) with profit before overhead, payroll, taxes, and interest of 28.37 M.
Arca Biopharma currently holds about 49.06 M in cash with (17.84 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.4, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Latest headline from www.nasdaq.com: Heres Why Were Watching ARCA biopharmas Cash Burn Situation - Nasdaq
President CEO, DirectorMichael Bristow
Average Analyst Recommendation
Analysts covering Arca Biopharma report their recommendations after researching Arca Biopharma's financial statements, talking to executives and customers, or listening in on Arca Biopharma's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Arca Biopharma. The Arca Biopharma consensus assessment is calculated by taking the average forecast from all of the analysts covering Arca Biopharma.
Strong Buy1 Opinion
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Arca Biopharma's available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Strong BuyUndervalued
Arca Biopharma (ABIO) is traded on NASDAQ Exchange in USA and employs 17 people. The company currently falls under 'Micro-Cap' category with current market capitalization of 30.69 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Arca Biopharma's market, we take the total number of its shares issued and multiply it by Arca Biopharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Arca Biopharma conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 14.41 M outstanding shares of which 71.36 K shares are presently shorted by private and institutional investors with about 1.51 trading days to cover. Arca Biopharma currently holds about 49.06 M in cash with (17.84 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.4, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Arca Biopharma Probability Of Bankruptcy
Ownership
Arca Biopharma retains a total of 14.41 Million outstanding shares. 30% of Arca Biopharma outstanding shares are owned by other corporate entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulation than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or about to change. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.

Ownership Allocation (%)

Check Arca Biopharma Ownership Details

Arca Biopharma Stock Price Odds Analysis

Proceeding from a normal probability distribution, the odds of Arca Biopharma jumping above the current price in 90 days from now is close to 99%. The Arca Biopharma probability density function shows the probability of Arca Biopharma stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days Arca Biopharma has a beta of 0.3789. This suggests as returns on the market go up, Arca Biopharma average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Arca Biopharma will be expected to be much smaller as well. Additionally, the company has a negative alpha, implying that the risk taken by holding this instrument is not justified. Arca Biopharma is significantly underperforming DOW.
  Odds Below 2.06HorizonTargetOdds Above 2.06
0.31%90 days
 2.06 
99.68%
Based on a normal probability distribution, the odds of Arca Biopharma to move above the current price in 90 days from now is close to 99 (This Arca Biopharma probability density function shows the probability of Arca Biopharma Stock to fall within a particular range of prices over 90 days) .

Arca Biopharma Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Arca Biopharma that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Arca Biopharma's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Arca Biopharma's value.
InstituionSecurity TypeTotal SharesValue
Susquehanna International Group LlpPut Options882.9 K2.2 M
Vanguard Group IncCommon Shares460.2 K1.1 M
Blackrock IncCommon Shares264.3 K658 K
Susquehanna International Group LlpCall Options121.2 K302 K
View Arca Biopharma Diagnostics

Arca Biopharma Risk Profiles

Investors will always prefer to have the highest possible return on investment while minimizing volatility. Arca Biopharma market risk premium is the additional return an investor will receive from holding Arca Biopharma long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Arca Biopharma. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Although Arca Biopharma's alpha and beta are two of the key measurements used to evaluate Arca Biopharma's performance over the market, the standard measures of volatility play an important role as well.

Arca Biopharma Stock Against Markets

Picking the right benchmark for Arca Biopharma stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Arca Biopharma stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Arca Biopharma is critical whether you are bullish or bearish towards Arca Biopharma at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Arca Biopharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Equity Analysis Now

   

Equity Analysis

Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
All  Next Launch Module

Arca Biopharma Corporate Directors

Arca Biopharma corporate directors refer to members of an Arca Biopharma board of directors. The board of directors generally takes responsibility for the Arca Biopharma's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Arca Biopharma's board members must vote for the resolution. The Arca Biopharma board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Raymond Woosley - DirectorProfile
Daniel Mitchell - DirectorProfile
Linda Grais - Lead Independent DirectorProfile
Anders Hove - DirectorProfile

Invested in Arca Biopharma?

The danger of trading Arca Biopharma is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Arca Biopharma is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Arca Biopharma. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Arca Biopharma is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Please continue to Trending Equities. You can also try Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.

Complementary Tools for analysis

When running Arca Biopharma price analysis, check to measure Arca Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arca Biopharma is operating at the current time. Most of Arca Biopharma's value examination focuses on studying past and present price action to predict the probability of Arca Biopharma's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Arca Biopharma's price. Additionally, you may evaluate how the addition of Arca Biopharma to your portfolios can decrease your overall portfolio volatility.
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Go
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Go
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Go
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
Is Arca Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Arca Biopharma. If investors know Arca Biopharma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Arca Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Arca Biopharma is measured differently than its book value, which is the value of Arca Biopharma that is recorded on the company's balance sheet. Investors also form their own opinion of Arca Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Arca Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Arca Biopharma's market value can be influenced by many factors that don't directly affect Arca Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Arca Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine Arca Biopharma value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Arca Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.